253 related articles for article (PubMed ID: 27535784)
1. Boning up on DPP4, DPP4 substrates, and DPP4-adipokine interactions: Logical reasoning and known facts about bone related effects of DPP4 inhibitors.
Glorie L; D'Haese PC; Verhulst A
Bone; 2016 Nov; 92():37-49. PubMed ID: 27535784
[TBL] [Abstract][Full Text] [Related]
2. The Multiple Biological Functions of Dipeptidyl Peptidase-4 in Bone Metabolism.
Yang Q; Fu B; Luo D; Wang H; Cao H; Chen X; Tian L; Yu X
Front Endocrinol (Lausanne); 2022; 13():856954. PubMed ID: 35586625
[TBL] [Abstract][Full Text] [Related]
3. Context-dependent effects of dipeptidyl peptidase 4 inhibitors.
Jackson EK
Curr Opin Nephrol Hypertens; 2017 Mar; 26(2):83-90. PubMed ID: 27898522
[TBL] [Abstract][Full Text] [Related]
4. Potential impact of sitagliptin on collagen-derived dipeptides in diabetic osteoporosis.
Baerts L; Glorie L; Maho W; Eelen A; Verhulst A; D'Haese P; Covaci A; De Meester I
Pharmacol Res; 2015 Oct; 100():336-40. PubMed ID: 26342756
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of neurodegeration in type 2 diabetes and the neuroprotective potential of dipeptidyl peptidase 4 inhibitors.
Matteucci E; Giampietro O
Curr Med Chem; 2015; 22(13):1573-81. PubMed ID: 25723507
[TBL] [Abstract][Full Text] [Related]
6. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.
Klemann C; Wagner L; Stephan M; von Hörsten S
Clin Exp Immunol; 2016 Jul; 185(1):1-21. PubMed ID: 26919392
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors.
Mulvihill EE; Drucker DJ
Endocr Rev; 2014 Dec; 35(6):992-1019. PubMed ID: 25216328
[TBL] [Abstract][Full Text] [Related]
8. DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury.
Glorie LL; Verhulst A; Matheeussen V; Baerts L; Magielse J; Hermans N; D'Haese PC; De Meester I; De Beuf A
Am J Physiol Renal Physiol; 2012 Sep; 303(5):F681-8. PubMed ID: 22718884
[TBL] [Abstract][Full Text] [Related]
9. Influence of Dipeptidyl Peptidase-4 (DPP4) on Mesenchymal Stem-Cell (MSC) Biology: Implications for Regenerative Medicine - Review.
Torrecillas-Baena B; Gálvez-Moreno MÁ; Quesada-Gómez JM; Dorado G; Casado-Díaz A
Stem Cell Rev Rep; 2022 Jan; 18(1):56-76. PubMed ID: 34677817
[TBL] [Abstract][Full Text] [Related]
10. An emerging role of dipeptidyl peptidase 4 (DPP4) beyond glucose control: potential implications in cardiovascular disease.
Zhong J; Rao X; Rajagopalan S
Atherosclerosis; 2013 Feb; 226(2):305-14. PubMed ID: 23083681
[TBL] [Abstract][Full Text] [Related]
11. The many facets of CD26/dipeptidyl peptidase 4 and its inhibitors in disorders of the CNS - a critical overview.
Bernstein HG; Keilhoff G; Dobrowolny H; Steiner J
Rev Neurosci; 2023 Jan; 34(1):1-24. PubMed ID: 35771831
[TBL] [Abstract][Full Text] [Related]
12. DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes.
Kim MK; Chae YN; Kim HD; Yang EK; Cho EJ; Choi SH; Cheong YH; Kim HS; Kim HJ; Jo YW; Son MH; Kim SH; Shin CY
Life Sci; 2012 Jan; 90(1-2):21-9. PubMed ID: 22056373
[TBL] [Abstract][Full Text] [Related]
13. The regulatory role of DPP4 in atherosclerotic disease.
Duan L; Rao X; Xia C; Rajagopalan S; Zhong J
Cardiovasc Diabetol; 2017 Jun; 16(1):76. PubMed ID: 28619058
[TBL] [Abstract][Full Text] [Related]
14. Effects of Inhibiting Dipeptidyl Peptidase-4 (DPP4) in Cows with Subclinical Ketosis.
Schulz K; Frahm J; Kersten S; Meyer U; Rehage J; Piechotta M; Meyerholz M; Breves G; Reiche D; Sauerwein H; Dänicke S
PLoS One; 2015; 10(8):e0136078. PubMed ID: 26291537
[TBL] [Abstract][Full Text] [Related]
15. Beneficial Effects of Evogliptin, a Novel Dipeptidyl Peptidase 4 Inhibitor, on Adiposity with Increased Ppargc1a in White Adipose Tissue in Obese Mice.
Chae YN; Kim TH; Kim MK; Shin CY; Jung IH; Sohn YS; Son MH
PLoS One; 2015; 10(12):e0144064. PubMed ID: 26633898
[TBL] [Abstract][Full Text] [Related]
16. Computer-Aided Screening of Phytoconstituents from
Sajal H; Patil SM; Raj R; Shbeer AM; Ageel M; Ramu R
Molecules; 2022 Aug; 27(16):. PubMed ID: 36014373
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of Porphyromonas gingivalis dipeptidyl peptidase 4 and structure-activity relationships based on inhibitor profiling.
Rea D; Van Elzen R; De Winter H; Van Goethem S; Landuyt B; Luyten W; Schoofs L; Van Der Veken P; Augustyns K; De Meester I; Fülöp V; Lambeir AM
Eur J Med Chem; 2017 Oct; 139():482-491. PubMed ID: 28826083
[TBL] [Abstract][Full Text] [Related]
18. Diabetes, hypertension, and chronic kidney disease progression: role of DPP4.
Nistala R; Savin V
Am J Physiol Renal Physiol; 2017 Apr; 312(4):F661-F670. PubMed ID: 28122713
[TBL] [Abstract][Full Text] [Related]
19. Use of dipeptidyl peptidase 4 inhibitors and fracture risk compared to use of other anti-hyperglycemic drugs.
Driessen JH; van Onzenoort HA; Starup-Linde J; Henry R; Neef C; van den Bergh J; Vestergaard P; de Vries F; Burden AM
Pharmacoepidemiol Drug Saf; 2015 Oct; 24(10):1017-25. PubMed ID: 26183226
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies.
Zhong J; Kankanala S; Rajagopalan S
Curr Opin Lipidol; 2016 Oct; 27(5):484-92. PubMed ID: 27472408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
